CONNECTA Therapeutics

Today, on World Fragile X Day, we stand in solidarity with the families and individuals affected by this genetic condition. At CONNECTA Therapeutics, we are dedicated to advancing research and developing innovative treatments to improve the lives of those with Fragile X syndrome. Fragile X syndrome, a leading cause of inherited intellectual disability, presents unique challenges that require our collective effort to address. Our team is committed to pushing the boundaries of science to bring hope and solutions to the Fragile X community. As we continue our journey towards developing a therapy, we are inspired by the resilience and strength of those living with Fragile X syndrome. We want to extend our heartfelt thanks to the organizations, researchers, and families whose support and collaboration are crucial to this important mission. Let's unite to raise awareness, support research, and advocate for a brighter future. Together we can make a difference.  https://lnkd.in/eGH4XFTJ #fxs #fragileX #fragilexawareness #22july2024 #fragilexinternational

We are excited to attend and be a sponsor of the XIII Simposi de Neurobiologia #NeuroSCB2024 #SimposiNeurobiologia2024 #NeurobiologySymposium2024 The Neurobiology Symposium is a biennial scientific event organized by the Neurobiology section of the Societat Catalana de Biologia (SCB), an institution funded in 1912 with the main objective of disseminating biological science in Catalunya. The main objective of the Symposium is to present recent scientific advances in the field of Neurosciences of the research groups of the Catalan community in order to be a scientific forum for participation of local, national and international researchers.

What happened last month in the #BioRegion⁉️ Let's review the busy month of February 👇 🔬 An antibody that neutralizes all SARS-CoV-2 variants has been developed in #Catalonia. 💹 Palabiofarma , WIVI vision, BiteRight, AFFIRMA BIOTECH SL & DOMMA have raised #funding. 🆕 The venture capital company Nina Capital has recorded its third investment vehicle to raise €50 million. 🔝 CONNECTA Therapeutics has received €2.7 million from public funding to start clinical trials of a drug targeted at treating fragile X syndrome (FXS). 🌎 Inbiomotion has reached its third distribution agreement for its breast cancer test, this one in the UK and Ireland. ✅ Peptomyc got positive results in its first clinical trial in patients. More relevant news here: 🔗https://tuit.cat/vp60v

💡 Barcelona is emerging as a global hub for innovation in Biotechnology, with countless startups introducing groundbreaking advancements each passing day. 🧬 Dive into our latest article to explore Barcelona's most influential biotech startups of 2023. 🚀 https://lnkd.in/d6z8r_mh The article features: deepull, Founded by Jordi Carrera and Rafel Bru Gibert, ONA Therapeutics, Founded by Salvador Aznar Benitah, and Valerie Vanhooren, Roka Furadada, Founded by Judit Camargo, CONNECTA Therapeutics Founded by Jordi Fabrega and Josep Prous, Kintsugi Therapeutics, Founded by Carmen Herrero Hernández and Marc Cusachs, BIOM Bioinspired Materials, Founded by Carlos Rodriguez-Caso, Javier Macia, and Ramon Farré-Escofet i Paris, INBRAIN Neuroelectronics, Founded by Anton Guimerà Brunet, Carolina Aguilar and Pedro José Garrido Sánchez, Luka Biondić, Founded by Claire Ponsford, John Bethell, and Simon Knowles, Pulmobiotics SL, Founded by Luis Serrano and Maria Lluch Senar, Libre Foods, Founded by Alan Iván Ramos, Accure Therapeutics, Founded by Laurent Nguyen Cong Duc and Pablo Villoslada Gate2Brain, Founded by Gloria Sancliments and Meritxell Teixido, NIMBLE Diagnostics Gyala Therapeutics FrontWave Imaging, Founded by Josep de la Puente, Susana Castel, and Òscar Calderón Agudo. Join the conversation and share your thoughts about these trailblazing startups making strides in the world of Biotechnology. Let's celebrate their contribution to global health and potential groundbreaking treatments on the horizon! 🎉 #Biotech #Startups #Innovation #Barcelona #HealthcareInnovation #GlobalHealth #EUStartups #BiotechnologyStartups

Today, 29 February, is a unique day in our calendar, as we celebrate World Rare Disease Day.   #rarediseases are diseases that have a low prevalence in the population, namely when they affect less than 5 per 10,000 inhabitants. On this year's international #RareDiseaseDay2024, we want to highlight that promoting research and study on rare diseases allows us to raise awareness and disseminate the struggle of all affected people, and increases the availability of orphan drugs, quickly and equitably for all patients.   It is essential to promote a global mobilisation to place the reality of these pathologies on the public agenda.   Vídeo: https://lnkd.in/eYtprMMq

Expansión 🗞 ⤵ https://lnkd.in/eDFUsWxE #CTH120 #FragileXSyndrome #FragileX #FXS #CNS #OrphanDrug #RareDiseaseDay #NextGenerationEU

CONNECTA Therapeutics, Centre for Genomic Regulation (CRG), Hospital del Mar Research Institute and Parc Taulí Research and Innovation Institute (I3PT) receive €2.7 million from the Ministry of Science and Innovation of Spain to begin Phase IIa trials for #CTH120 in #FragileXSyndrome. Learn more on our website: https://lnkd.in/dt2W6Jrj #FragileX #CNS #OrphanDrug #RareDiseaseDay #NextGenerationEU

Today is International Fragile X Awareness Day. At CONNECTA Therapeutics we are committed to raising awarenesss of #fragilexsyndrome #internationalfragilexawarenessday